Kerryn Butler
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kerryn Butler has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Lucy Burns
National Drug and Alcohol Research Centre, University of New South Wales, Sydney, Australia
14 shared publications Raimondo Bruno
University of Tasmania, Hobart, Australia
7 shared publications- Allison Matthews
School of Psychological Sciences, University of Tasmania
5 shared publications Sarah Larney
National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, Australia; Département de médecine famille et de médecine d'urgence/Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, Canada
5 shared publications- Simon Lenton
Curtin University
5 shared publications - Rachel Sutherland
National Drug and Alcohol Research Centre, UNSW Sydney Sydney Australia
4 shared publications
Latest Publications
- 1 November 2021
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 228, 109050
Hepatitis C virus cascade of care among people who inject drugs in Australia: Factors associated with testing and treatment in a universal healthcare system
- 1 November 2021
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 228, 109050
Hepatitis C virus cascade of care among people who inject drugs in Australia: Factors associated with testing and treatment in a universal healthcare system
- 23 March 2021
- Published by Wiley in Drug and Alcohol Review
- Vol. 40 (7) , 1349-1353
Concordance between self‐reported and current hepatitis C virus infection status in a sample of people who inject drugs in Sydney and Canberra, Australia
Introduction: Awareness of hepatitis C virus (HCV) status among people who inject drugs is critical to ensure linkage to care and reduce transmission risk. Testing pathways, confusion about results and possible reinfection raise potential for discordance between perceived and actual HCV status among people who inject drugs. We evaluated self‐reported and serologically confirmed HCV status concordance among a sample of Australian people who inject drugs.Methods: Data were collected in May–June 2018 from participants in Canberra and Sydney, Australia, who had injected drugs at least monthly in the past 6 months. Participants completed a structured interview assessing self‐reported HCV status and provided a dried blood spot sample for HCV RNA testing.Results: Of 103 participants, 95% self‐reported ever receiving antibody testing, 58% of whom reported having received RNA testing. Seventy‐three percent of participants reported never having been told that they had HCV, 18% reported current infection and 9% did not know their current status. According to dried blood spot RNA testing, 20% were currently infected. Over a quarter of the sample (28%, n = 29) did not accurately report their HCV status, half of whom were unaware of a current infection.Discussion and Conclusions: With over one‐quarter of the sample in our study not accurately reporting their current HCV status, our findings reinforce the importance of regular testing for active infection, and the need for improved health literacy on HCV antibody and RNA test results, HCV status post‐treatment and reinfection risk.
- 23 March 2021
- Published by Wiley in Drug and Alcohol Review
- Vol. 40 (7) , 1349-1353
Concordance between self‐reported and current hepatitis C virus infection status in a sample of people who inject drugs in Sydney and Canberra, Australia
Introduction: Awareness of hepatitis C virus (HCV) status among people who inject drugs is critical to ensure linkage to care and reduce transmission risk. Testing pathways, confusion about results and possible reinfection raise potential for discordance between perceived and actual HCV status among people who inject drugs. We evaluated self‐reported and serologically confirmed HCV status concordance among a sample of Australian people who inject drugs.Methods: Data were collected in May–June 2018 from participants in Canberra and Sydney, Australia, who had injected drugs at least monthly in the past 6 months. Participants completed a structured interview assessing self‐reported HCV status and provided a dried blood spot sample for HCV RNA testing.Results: Of 103 participants, 95% self‐reported ever receiving antibody testing, 58% of whom reported having received RNA testing. Seventy‐three percent of participants reported never having been told that they had HCV, 18% reported current infection and 9% did not know their current status. According to dried blood spot RNA testing, 20% were currently infected. Over a quarter of the sample (28%, n = 29) did not accurately report their HCV status, half of whom were unaware of a current infection.Discussion and Conclusions: With over one‐quarter of the sample in our study not accurately reporting their current HCV status, our findings reinforce the importance of regular testing for active infection, and the need for improved health literacy on HCV antibody and RNA test results, HCV status post‐treatment and reinfection risk.
- 24 May 2020
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 73 (1) , e107-e118
Association Between Opioid Agonist Therapy and Testing, Treatment Uptake, and Treatment Outcomes for Hepatitis C Infection Among People Who Inject Drugs: A Systematic Review and Meta-analysis
Background: People who inject drugs (PWID) experience barriers to accessing testing and treatment for hepatitis C virus (HCV) infection. Opioid agonist therapy (OAT) may provide an opportunity to improve access to HCV care. This systematic review assessed the association of OAT and HCV testing, treatment, and treatment outcomes among PWID. Methods: Bibliographic databases and conference presentations were searched for studies that assessed the association between OAT and HCV testing, treatment, and treatment outcomes (direct-acting antiviral [DAA] therapy only) among PWID (in the past year). Meta-analysis was used to pool estimates. Results: Of 9877 articles identified, 22 studies conducted in Australia, Europe, North America, and Thailand were eligible and included. Risk of bias was serious in 21 studies and moderate in 1 study. Current/recent OAT was associated with an increased odds of recent HCV antibody testing (4 studies; odds ratio (OR), 1.80; 95% confidence interval [CI], 1.36–2.39), HCV RNA testing among those who were HCV antibody–positive (2 studies; OR, 1.83; 95% CI, 1.27–2.62), and DAA treatment uptake among those who were HCV RNA–positive (7 studies; OR, 1.53; 95% CI, 1.07–2.20). There was insufficient evidence of an association between OAT and treatment completion (9 studies) or sustained virologic response following DAA therapy (9 studies). Conclusions: OAT can increase linkage to HCV care, including uptake of HCV testing and treatment among PWID. This supports the scale-up of OAT as part of strategies to enhance HCV treatment to further HCV elimination efforts.
- 24 May 2020
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 73 (1) , e107-e118
Association Between Opioid Agonist Therapy and Testing, Treatment Uptake, and Treatment Outcomes for Hepatitis C Infection Among People Who Inject Drugs: A Systematic Review and Meta-analysis
Background: People who inject drugs (PWID) experience barriers to accessing testing and treatment for hepatitis C virus (HCV) infection. Opioid agonist therapy (OAT) may provide an opportunity to improve access to HCV care. This systematic review assessed the association of OAT and HCV testing, treatment, and treatment outcomes among PWID. Methods: Bibliographic databases and conference presentations were searched for studies that assessed the association between OAT and HCV testing, treatment, and treatment outcomes (direct-acting antiviral [DAA] therapy only) among PWID (in the past year). Meta-analysis was used to pool estimates. Results: Of 9877 articles identified, 22 studies conducted in Australia, Europe, North America, and Thailand were eligible and included. Risk of bias was serious in 21 studies and moderate in 1 study. Current/recent OAT was associated with an increased odds of recent HCV antibody testing (4 studies; odds ratio (OR), 1.80; 95% confidence interval [CI], 1.36–2.39), HCV RNA testing among those who were HCV antibody–positive (2 studies; OR, 1.83; 95% CI, 1.27–2.62), and DAA treatment uptake among those who were HCV RNA–positive (7 studies; OR, 1.53; 95% CI, 1.07–2.20). There was insufficient evidence of an association between OAT and treatment completion (9 studies) or sustained virologic response following DAA therapy (9 studies). Conclusions: OAT can increase linkage to HCV care, including uptake of HCV testing and treatment among PWID. This supports the scale-up of OAT as part of strategies to enhance HCV treatment to further HCV elimination efforts.
- 11 December 2019
- Published by Wiley in Drug and Alcohol Review
- Vol. 39 (1) , 83-92
Use of alcohol swabs to clean injecting sites among people who regularly inject drugs in Australia
Introduction and Aims: Cleaning drug injection sites with alcohol swabs prior to injecting reduces risk of abscesses and other skin and soft tissue infections (SSTI). Better understanding of swabbing behaviours can inform interventions to improve injecting hygiene. We aimed to determine the socio‐demographic, drug use and injecting risk exposure correlates of swabbing prior to injecting and reasons for not swabbing.Design and Methods: The Illicit Drug Reporting System recruited participants who had injected drugs at least monthly in the past six months in June–July 2017 from all Australian capital cities via needle and syringe programs and word‐of‐mouth. A structured interview was used to collect information on drug use and related behaviour, as well as swabbing practices. Logistic regression was used to identify factors associated with not swabbing at last injection.Results: Of 853 respondents, one‐quarter (26%) reported that they did not swab prior to their last injection. In adjusted analyses, crystal methamphetamine as the last drug injected, past month receptive or distributive syringe sharing, and past month re‐use of one's own needle were significantly associated with not swabbing at last injection. Among participants who did not swab at last injection, swabbing was frequently considered unnecessary and a small number disliked using alcohol swabs.Discussion and Conclusions: Efforts are needed to increase awareness of the importance of injecting hygiene in preventing SSTI. Interventions to increase swabbing should be included as part of a wider package of injecting hygiene education, particularly in light of associations with receptive and/or distributive syringe sharing.
- 11 December 2019
- Published by Wiley in Drug and Alcohol Review
- Vol. 39 (1) , 83-92
Use of alcohol swabs to clean injecting sites among people who regularly inject drugs in Australia
Introduction and Aims: Cleaning drug injection sites with alcohol swabs prior to injecting reduces risk of abscesses and other skin and soft tissue infections (SSTI). Better understanding of swabbing behaviours can inform interventions to improve injecting hygiene. We aimed to determine the socio‐demographic, drug use and injecting risk exposure correlates of swabbing prior to injecting and reasons for not swabbing.Design and Methods: The Illicit Drug Reporting System recruited participants who had injected drugs at least monthly in the past six months in June–July 2017 from all Australian capital cities via needle and syringe programs and word‐of‐mouth. A structured interview was used to collect information on drug use and related behaviour, as well as swabbing practices. Logistic regression was used to identify factors associated with not swabbing at last injection.Results: Of 853 respondents, one‐quarter (26%) reported that they did not swab prior to their last injection. In adjusted analyses, crystal methamphetamine as the last drug injected, past month receptive or distributive syringe sharing, and past month re‐use of one's own needle were significantly associated with not swabbing at last injection. Among participants who did not swab at last injection, swabbing was frequently considered unnecessary and a small number disliked using alcohol swabs.Discussion and Conclusions: Efforts are needed to increase awareness of the importance of injecting hygiene in preventing SSTI. Interventions to increase swabbing should be included as part of a wider package of injecting hygiene education, particularly in light of associations with receptive and/or distributive syringe sharing.
- 12 December 2018
- Published by Wiley in Drug and Alcohol Review
- Vol. 38 (3) , 264-269
Uptake of direct acting antiviral therapies for the treatment of hepatitis C virus among people who inject drugs in a universal health‐care system
Introduction and Aims: Direct acting antiviral (DAA) treatment can reduce hepatitis C virus (HCV) infection incidence and mortality, although large scale uptake of these treatments is necessary to achieve those reductions. Targeting people who inject drugs (PWID) will be crucial to achieve the necessary reductions. Previously, treatment uptake has been very low (1–2%) among PWID, but these new DAAs have been subsidised in Australia since March 2016. This study describes treatment uptake among a sample of PWID in Australia and examines sociodemographic and drug use variables associated with treatment uptake.Design and Methods: An Australian national cross‐sectional sample (n = 817) of regular PWID drawn from a convenience sentinel sample aged ≥18 years. Information on demographics, drug use, HCV antibody testing, RNA testing, recent DAA treatment initiation and DAA prescriber settings was collected via an interviewer‐administered survey.Results: There were 291 HCV RNA positive participants, of who one‐third reported initiating DAA treatment since the introduction of subsidised DAA medications. Current opioid substitution treatment was significantly associated with increased treatment uptake (adjusted odds ratio 2.20, 95% confidence interval 1.31, 3.68) while those with unstable housing were less likely to initiate treatment (adjusted odds ratio 0.42, 95% confidence interval 0.22, 0.82).Discussion and Conclusions: This study found that DAA treatment uptake has increased among current PWID, a priority population for treatment. Efforts to maintain this uptake through linking current PWID with treatment providers through harm reduction services such as opioid substitution therapy, needle and syringe programs, and outreach services are required to meet incidence and mortality reduction targets.
- 12 December 2018
- Published by Wiley in Drug and Alcohol Review
- Vol. 38 (3) , 264-269
Uptake of direct acting antiviral therapies for the treatment of hepatitis C virus among people who inject drugs in a universal health‐care system
Introduction and Aims: Direct acting antiviral (DAA) treatment can reduce hepatitis C virus (HCV) infection incidence and mortality, although large scale uptake of these treatments is necessary to achieve those reductions. Targeting people who inject drugs (PWID) will be crucial to achieve the necessary reductions. Previously, treatment uptake has been very low (1–2%) among PWID, but these new DAAs have been subsidised in Australia since March 2016. This study describes treatment uptake among a sample of PWID in Australia and examines sociodemographic and drug use variables associated with treatment uptake.Design and Methods: An Australian national cross‐sectional sample (n = 817) of regular PWID drawn from a convenience sentinel sample aged ≥18 years. Information on demographics, drug use, HCV antibody testing, RNA testing, recent DAA treatment initiation and DAA prescriber settings was collected via an interviewer‐administered survey.Results: There were 291 HCV RNA positive participants, of who one‐third reported initiating DAA treatment since the introduction of subsidised DAA medications. Current opioid substitution treatment was significantly associated with increased treatment uptake (adjusted odds ratio 2.20, 95% confidence interval 1.31, 3.68) while those with unstable housing were less likely to initiate treatment (adjusted odds ratio 0.42, 95% confidence interval 0.22, 0.82).Discussion and Conclusions: This study found that DAA treatment uptake has increased among current PWID, a priority population for treatment. Efforts to maintain this uptake through linking current PWID with treatment providers through harm reduction services such as opioid substitution therapy, needle and syringe programs, and outreach services are required to meet incidence and mortality reduction targets.
- 1 September 2017
- Published by Elsevier in International Journal of Drug Policy
- Vol. 47, 102-106
Hepatitis C testing in general practice settings: A cross-sectional study of people who inject drugs in Australia
- 1 September 2017
- Published by Elsevier in International Journal of Drug Policy
- Vol. 47, 102-106
Hepatitis C testing in general practice settings: A cross-sectional study of people who inject drugs in Australia
- 1 May 2017
- Published by Elsevier in International Journal of Drug Policy
- Vol. 43, 23-32
Motivations for new psychoactive substance use among regular psychostimulant users in Australia
- 1 May 2017
- Published by Elsevier in International Journal of Drug Policy
- Vol. 43, 23-32
Motivations for new psychoactive substance use among regular psychostimulant users in Australia
- Open Access
- 30 September 2016
- Published by CSIRO Publishing in Public Health Research and Practice
- Vol. 26 (4)
Estimating prevalence of drug and alcohol presentations to hospital emergency departments in NSW, Australia: impact of hospital consultation liaison services
The impact of drug and alcohol misuse has been the subject of widespread media discussion in the past year, particularly in the context of restricted alcohol trading hours in an effort to reduce alcohol-fuelled violence. A recent study evaluating NSW Health’s drug and alcohol consultation liaison (CL) services1 demonstrates how pervasive drug and alcohol problems are, and the impact they have on the health system. This paper highlights how expanding CL services to fill current unmet need could deliver a range of benefits to patients and hospitals.
- 30 September 2016
- Published by CSIRO Publishing in Public Health Research and Practice
- Vol. 26 (4)
Open AccessEstimating prevalence of drug and alcohol presentations to hospital emergency departments in NSW, Australia: impact of hospital consultation liaison services
The impact of drug and alcohol misuse has been the subject of widespread media discussion in the past year, particularly in the context of restricted alcohol trading hours in an effort to reduce alcohol-fuelled violence. A recent study evaluating NSW Health’s drug and alcohol consultation liaison (CL) services1 demonstrates how pervasive drug and alcohol problems are, and the impact they have on the health system. This paper highlights how expanding CL services to fill current unmet need could deliver a range of benefits to patients and hospitals.